GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Pentixapharm Holding PTP.DE · EUR

Health Care · XETRA · 🇩🇪 Germany

Compare

1.98

-1.00%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in EUR, from our data supplier.

FY2025

Revenue

€93,000

FY2021FY2025

Net income

−€16.5m

FY2021FY2025

Free cash flow

−€18.6m

FY2021FY2025

Shareholders' equity

€35.1m

FY2021FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Revenue€93,000€118,000€24,000€31,000€59,000
Research and development€205,000—€8.3m€4.3m€2.9m
Operating income−€19.6m−€17.6m−€6.2m−€779,000—
Net income−€16.5m−€12.8m−€7.6m−€2.0m−€2.5m
Diluted earnings per share-0.64-0.52-0.30-0.08-0.10

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Total assets€41.9m€67.4m€73.4m€53.9m€29.1m
Total liabilities€6.8m€18.0m€24.9m€15.4m€1.3m
Shareholders' equity€35.1m€49.4m€48.5m€38.5m€27.9m
Shares outstanding26m25m26m26m26m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Cash from operations−€18.0m−€4.3m€2.1m−€2.2m−€1.4m
Capital spending−€625,000−€1,000−€4.9m−€4.0m−€2.7m
Free cash flow−€18.6m−€4.3m−€2.8m−€6.2m−€4.1m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue——−€24,000€79,000€19,000€19,000€118,000—
Operating income−€3.6m−€3.0m−€6.4m−€4.6m−€4.5m−€4.2m−€17.5m−€147,000
Net income−€3.7m−€3.2m−€3.8m−€4.3m−€4.4m−€4.0m−€12.7m−€147,000
Diluted earnings per share-0.14-0.12-0.15-0.17-0.17-0.16-0.51-0.01
Cash from operations−€2.0m−€2.0m−€2.0m−€7.0m−€3.0m−€5.0m−€4.0m—
Total assets€38.5m€41.2m€41.9m€43.0m€51.1m€55.5m€67.4m€488,000
Cash and short-term investments———————€4,000
Shareholders' equity€28.5m€32.2m€35.1m€36.7m€41.0m€45.4m€49.4m€1,000

Growth per year

Compound annual rate

3 years5 years10 years
Revenue44.2%——
Operating income193.0%——
Net income103.4%——

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings-2.3-5.7
Price to sales412.1—

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.